INFO & CONTACTS:  +39 02 2390 1

A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate Precemtabart Tocentecan (M9140) in Participants With Advanced Solid Tumors (Master Protocol)

Phase: Phase I-II clinical trials

Principal Investigator: Dott.ssa Damian Silvia

Main Facility: Oncologia Medica 1

Drug: Precemtabart Tocentecan (M9140)

Pathologies: Pancreatic cancer, Lung cancer, Stomach tumors

ClinicalTrials.gov: Read the details about clinical trials

Study aims to investigate the clinical activity of precemtabart tocentecan (M9140), an antibody-drug conjugate specific to carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) in adults multiple tumor types which express CEACAM5. 

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe